Long intergenic non-protein coding RNA 189 (LINC00189)

Long intergenic non-protein coding RNA 189 (LINC00189), also known as C21orf109 and NCRNA00189, is a long non-coding RNA (lncRNA) that does not code for proteins but participates in the regulation of gene expression[1]. LINC00189 has recently emerged as a key RNA implicated in the progression of various cancers, demonstrating association with adverse clinical outcomes such as tumor recurrence and poor prognosis[1]. Studies have identified LINC00189 as a hub gene within co-expression networks in squamous cell carcinoma of the bladder, suggesting a regulatory role in intratumoral heterogeneity and oncogenic signaling[1]. Furthermore, elevated expression of LINC00189 in cervical cancer correlates with worse recurrence-free survival, indicating its potential utility as a prognostic biomarker and candidate therapeutic target[1]. The precise molecular mechanisms underlying the functions of LINC00189 remain under investigation, but current evidence points to a critical role in tumor pathogenesis and recurrence. LINC00189 belongs to the family of long intergenic non-coding RNAs, a subclass of lncRNAs that are transcriptionally active RNA molecules longer than 200 nucleotides with no protein-coding capacity or overlap with annotated genes[4]. Key points: - LINC00189 is not a protein-coding gene nor a classical therapeutic target such as a receptor or enzyme, but it does represent a *candidate RNA-based therapeutic target* due to its regulatory role in cancer biology[1]. - There are no known direct-acting drugs or drug classes that modulate LINC00189, nor are there established mechanisms of action or safety profiles for its pharmacological targeting as of this time. - LINC00189 is under study mainly as a *prognostic biomarker* in oncology[1]. - Alternative names include C21orf109 and NCRNA00189[1].

Other names

C21orf109NCRNA00189LINC00189